JP2025508066A5 - - Google Patents

Info

Publication number
JP2025508066A5
JP2025508066A5 JP2024553409A JP2024553409A JP2025508066A5 JP 2025508066 A5 JP2025508066 A5 JP 2025508066A5 JP 2024553409 A JP2024553409 A JP 2024553409A JP 2024553409 A JP2024553409 A JP 2024553409A JP 2025508066 A5 JP2025508066 A5 JP 2025508066A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
seq
light chain
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024553409A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025508066A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2023/000124 external-priority patent/WO2023170474A1/en
Publication of JP2025508066A publication Critical patent/JP2025508066A/ja
Publication of JP2025508066A5 publication Critical patent/JP2025508066A5/ja
Pending legal-status Critical Current

Links

JP2024553409A 2022-03-07 2023-03-07 目的としたt細胞活性化のためのcd28二重特異性抗体 Pending JP2025508066A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263317491P 2022-03-07 2022-03-07
US63/317,491 2022-03-07
US202263323893P 2022-03-25 2022-03-25
US63/323,893 2022-03-25
PCT/IB2023/000124 WO2023170474A1 (en) 2022-03-07 2023-03-07 Cd28 bispecific antibodies for targeted t cell activation

Publications (2)

Publication Number Publication Date
JP2025508066A JP2025508066A (ja) 2025-03-21
JP2025508066A5 true JP2025508066A5 (cg-RX-API-DMAC7.html) 2026-03-17

Family

ID=86272440

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024553409A Pending JP2025508066A (ja) 2022-03-07 2023-03-07 目的としたt細胞活性化のためのcd28二重特異性抗体

Country Status (8)

Country Link
US (1) US20240002544A1 (cg-RX-API-DMAC7.html)
EP (1) EP4490192A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025508066A (cg-RX-API-DMAC7.html)
CN (1) CN119233993A (cg-RX-API-DMAC7.html)
AU (1) AU2023232992A1 (cg-RX-API-DMAC7.html)
CA (1) CA3249273A1 (cg-RX-API-DMAC7.html)
IL (1) IL314916A (cg-RX-API-DMAC7.html)
WO (1) WO2023170474A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024512574A (ja) * 2021-03-22 2024-03-19 ノビミューン エスアー Cd47およびpd-l1を標的とする二重特異性抗体ならびにその使用方法
WO2023174925A1 (en) 2022-03-14 2023-09-21 Novimmune Sa Bispecific gpc3xcd28 and gpc3xcd3 antibodies and their combination for targeted killing of gpc3 positive malignant cells
AU2023362569A1 (en) * 2022-10-21 2025-04-24 Novimmune Sa Pd-l1xcd28 bispecific antibodies for immune checkpoint-dependent t cell activation
WO2025051895A1 (en) * 2023-09-06 2025-03-13 Novimmune Sa Combination therapy with a cea x cd28 bispecific antibody and blocking anti-pd-1 antibodies for enhanced in vivo anti-tumor activity
TW202544034A (zh) * 2024-05-06 2025-11-16 美商榮都醫療公司 結合至cd28及nectin-4之雙特異性抗體
WO2026078067A1 (en) 2024-10-08 2026-04-16 Novimmune Sa Fcrh5 monospecific antibodies and derived fcrh5xcd28 bispecific antibodies and use thereof

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
WO2006028936A2 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
WO2006050949A2 (de) 2004-11-11 2006-05-18 Tegenero Ag Superagonistische anti-cd28 antikörper
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
US9067986B2 (en) 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
PT2560993T (pt) 2010-04-20 2024-09-16 Genmab As Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas
WO2012023053A2 (en) 2010-08-16 2012-02-23 Novimmune S.A. Methods for the generation of multispecific and multivalent antibodies
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
KR101981342B1 (ko) 2011-03-02 2019-05-22 로슈 글리카트 아게 Cea 항체
US9574010B2 (en) 2011-11-04 2017-02-21 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the Fc domain
CN110437337B (zh) 2013-02-26 2024-07-30 罗切格利卡特公司 双特异性t细胞活化性抗原结合分子
WO2016036678A1 (en) 2014-09-02 2016-03-10 Medimmune, Llc Formulations of bispecific antibodies
US10730954B2 (en) 2017-05-12 2020-08-04 Harpoon Therapeutics, Inc. MSLN targeting trispecific proteins and methods of use
US11260117B2 (en) * 2017-05-26 2022-03-01 Novimmune Sa Anti-CD47 x anti-mesothelin antibodies and methods of use thereof
WO2019016411A1 (en) * 2017-07-21 2019-01-24 Novimmune Sa GENERATION OF MULTISPECIFIC ANTIBODY MIXTURES AND METHODS OF USE
CN112566938B (zh) * 2018-06-03 2025-04-01 拉姆卡普生物测试有限公司 针对ceacam5和cd47的双特异性抗体
CN119143875A (zh) 2018-06-21 2024-12-17 瑞泽恩制药公司 双特异性抗psma x抗cd28抗体及其用途
KR20210104836A (ko) 2018-12-19 2021-08-25 리제너론 파아마슈티컬스, 인크. 이중 특이적 항-cd28 x 항-cd22 항체 및 그의 용도
WO2020132024A1 (en) 2018-12-19 2020-06-25 Regeneron Pharmaceuticals, Inc. Bispecific anti-muc16 x anti-cd28 antibodies and uses thereof
CR20210326A (es) 2018-12-21 2021-09-10 Hoffmann La Roche Moléculas agonistas de unión al antígeno cd28 que actúan sobre el tumor
US20200223925A1 (en) 2018-12-21 2020-07-16 Hoffmann-La Roche Inc. Tumor-targeted superagonistic cd28 antigen binding molecules
EP3941941A1 (en) 2019-03-22 2022-01-26 Regeneron Pharmaceuticals, Inc. Egfr x cd28 multispecific antibodies
AU2020350205A1 (en) 2019-09-18 2022-05-12 Lamkap Bio Alpha AG Bispecific antibodies against CEACAM5 and CD3
EP3831849A1 (en) 2019-12-02 2021-06-09 LamKap Bio beta AG Bispecific antibodies against ceacam5 and cd47
EP4097129A1 (en) 2020-01-29 2022-12-07 Inhibrx, Inc. Cd28 single domain antibodies and multivalent and multispecific constructs thereof
CR20220627A (es) 2020-06-23 2023-02-17 Hoffmann La Roche Moléculas agonistas de unión al antígeno cd28 que se derigen a her2
US11919958B2 (en) 2020-08-19 2024-03-05 Xencor, Inc. Anti-CD28 compositions
KR20230121772A (ko) * 2020-12-18 2023-08-21 람카프 바이오 베타 엘티디. Ceacam5 및 cd47에 대한 이중특이적 항체

Similar Documents

Publication Publication Date Title
JP2024504384A5 (cg-RX-API-DMAC7.html)
JP2025160458A5 (cg-RX-API-DMAC7.html)
JP2021534096A5 (cg-RX-API-DMAC7.html)
JP2021533159A5 (cg-RX-API-DMAC7.html)
JP2022075818A5 (cg-RX-API-DMAC7.html)
JP2020079252A5 (cg-RX-API-DMAC7.html)
JP2023509448A5 (cg-RX-API-DMAC7.html)
JP2023123726A5 (cg-RX-API-DMAC7.html)
JP2023134618A5 (cg-RX-API-DMAC7.html)
JP2024542194A5 (cg-RX-API-DMAC7.html)
JP2022533538A5 (cg-RX-API-DMAC7.html)
RU2017134495A (ru) Антитела к альфа-рецептору собачьего интерлейкина-4
JP2023549537A5 (cg-RX-API-DMAC7.html)
JP2023540526A5 (cg-RX-API-DMAC7.html)
RU2009129403A (ru) Антитела, нейтрализующие цитомегаловирус человека, и их применение
JP2022525377A5 (cg-RX-API-DMAC7.html)
JP2021520832A5 (cg-RX-API-DMAC7.html)
JP2023548529A5 (cg-RX-API-DMAC7.html)
JP2024001073A5 (cg-RX-API-DMAC7.html)
JP2024532489A5 (cg-RX-API-DMAC7.html)
JP2025501775A5 (cg-RX-API-DMAC7.html)
JP2024540148A5 (cg-RX-API-DMAC7.html)
JP2023509373A5 (cg-RX-API-DMAC7.html)
JP2021511387A5 (cg-RX-API-DMAC7.html)
JP2023510982A5 (cg-RX-API-DMAC7.html)